Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of KarXT for manic episodes in bipolar I disorder
MOH_2025-06-22_014026Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trospium in bipolar I disorder and mania (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary endpoint not reported. Started Jun 2025; status: recruiting.
02
Drugs
trospium
03
Conditions
bipolar I disordermania
Beyond the preview
Go deeper on MOH_2025-06-22_014026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-22_014026.